Pusztaszeri Marc P, Maleki Zahra
Department of Pathology, McGill University, Montreal, Quebec, Canada.
Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland, USA.
Cancer Cytopathol. 2025 Jun;133(6):e70023. doi: 10.1002/cncy.70023.
Medullary thyroid carcinoma (MTC) is a rare but potentially aggressive neuroendocrine tumor arising from the thyroid C cells (parafollicular cells) that produce calcitonin, representing 1%-3% of thyroid malignancies but contributing to up to 15% of thyroid cancer-related deaths. Early detection is critical for improving survival and outcomes because its tumor origin, treatment, and prognosis differ completely from papillary thyroid carcinoma. However, the low incidence of MTC and its variable cytomorphology can pose significant diagnostic challenges for cytopathologists. Referred to as the great mimicker, MTC can resemble various primary and metastatic tumors, complicating its identification, particularly in fine-needle aspiration (FNA) biopsies. Reported FNA sensitivity for a specific MTC diagnosis varies widely from 12.5% to 88.2%, with a 2014 meta-analysis estimating an overall sensitivity of 56.5% when including suspicious lesions. False-negative FNA results, often caused by misinterpretation of cytologic features or inadequate specimen quality, can lead to delayed or suboptimal treatment. Pathologists must be familiar with MTC's diverse cytopathologic presentation and maintain a low threshold for additional diagnostic tests to ensure an accurate preoperative diagnosis. This review article provides practical guidance on diagnosing MTC, emphasizing cytologic features, ancillary studies, mimickers, and common diagnostic pitfalls, serving as a valuable resource for cytopathologists, general pathologists, and trainees to improve diagnostic accuracy and patient care.
甲状腺髓样癌(MTC)是一种罕见但具有潜在侵袭性的神经内分泌肿瘤,起源于产生降钙素的甲状腺C细胞(滤泡旁细胞),占甲状腺恶性肿瘤的1%-3%,但在甲状腺癌相关死亡中所占比例高达15%。早期检测对于提高生存率和改善预后至关重要,因为其肿瘤起源、治疗和预后与甲状腺乳头状癌完全不同。然而,MTC的低发病率及其多变的细胞形态学特征可能给细胞病理学家带来重大的诊断挑战。MTC被称为“大模仿者”,它可以类似于各种原发性和转移性肿瘤,使其识别变得复杂,尤其是在细针穿刺(FNA)活检中。报道的FNA对特定MTC诊断的敏感性差异很大,从12.5%到88.2%不等,2014年的一项荟萃分析估计,包括可疑病变时总体敏感性为56.5%。FNA假阴性结果通常是由于对细胞学特征的错误解读或标本质量不足导致的,可能会导致治疗延迟或治疗效果不佳。病理学家必须熟悉MTC多样的细胞病理学表现,并对额外的诊断测试保持较低的阈值,以确保术前准确诊断。这篇综述文章提供了诊断MTC的实用指南,强调了细胞学特征、辅助研究、模仿者和常见的诊断陷阱,为细胞病理学家、普通病理学家和实习生提高诊断准确性和患者护理水平提供了宝贵的资源。